# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Six patients with Stargardt disease have been dosed in the Phase 1/2 clinical trial to date in the low dose cohort and medium d...
Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, develop...
Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:OCGN) with a Buy and maintains $5 price target.